Adaptimmune Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	60.28	27.15	6.15
Revenue Growth (YoY)	-	-	122.05%	341.50%	55.36%
Gross Profit	5.92	-	60.28	27.15	6.15
Selling, General & Admin	-	-	75.67	63.39	57.31
Research & Development	-	-	144.27	127.73	111.09
Other Operating Expenses	-5.12	4.62	-2.96	-	-
Total Operating Expenses	-5.12	4.62	216.99	191.11	168.4
Operating Income	-72.57	-182.94	-156.7	-163.97	-162.25
Interest Income	2.17	6.6	5.96	1.54	1.1
Interest Expense	-7.27	-6.57	-2.12	-	-
Other Non-Operating Income (Expense)	-0.34	-	22.05	-0.54	3.85
Total Non-Operating Income (Expense)	-5.43	0.02	25.9	1.01	4.95
Pretax Income	-78.01	-182.92	-130.81	-162.96	-157.3
Provision for Income Taxes	-	-	13.73	-2.5	-0.79
Net Income	25.21	-71.88	-117.08	-160.46	-156.51
Earnings From Discontinued Operations	103.21	105	-	-	-
Net Income to Common	128.42	33.12	-117.08	-165.46	-158.09
Net Income Growth	287.75%	-	-	-	-
Shares Outstanding (Basic)	1,577	1,514	1,206	967	935
Shares Outstanding (Diluted)	1,634	1,766	1,206	967	935
Shares Change (YoY)	-7.45%	46.39%	24.73%	3.47%	9.37%
EPS (Basic)	0.02	-0.04	-0.10	-0.17	-0.17
EPS (Diluted)	0.02	-0.04	-0.10	-0.17	-0.17
Free Cash Flow	-248.98	-181.49	-277.74	-171.27	2.16
Free Cash Flow Per Share	-0.15	-0.10	-0.23	-0.18	0.00
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-259.96%	-603.97%	-2638.58%
Profit Margin	-	-	-194.23%	-591.06%	-2545.26%
FCF Margin	-	-	-460.75%	-630.86%	35.05%
EBITDA	-61.27	-166.95	-147.03	-157.89	-155.68
EBITDA Margin	-	-	-243.90%	-581.59%	-2531.78%
EBIT	-72.57	-182.94	-156.7	-163.97	-162.25
EBIT Margin	-	-	-259.96%	-603.97%	-2638.58%
Effective Tax Rate	0.00%	0.00%	-10.49%	1.53%	0.50%